scholarly journals Current Role of Adjuvant Therapy in High Risk for Recurrence Resected Kidney Cancer

2020 ◽  
Author(s):  
Fadil Hassan ◽  
Shahid Lambe ◽  
Kiran Sharma ◽  
Anil Kapoor
Keyword(s):  
High Risk ◽  
Adjuvant Therapy ◽  
Kidney Cancer ◽  
Current Role

scholarly journals Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials

2018 ◽  
Vol 199 (1) ◽  
pp. 43-52 ◽  
Author(s):  
Andrew T. Lenis ◽  
Nicholas M. Donin ◽  
David C. Johnson ◽  
Izak Faiena ◽  
Amirali Salmasi ◽  
...  
Keyword(s):  
Clinical Trials ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Kidney Cancer

scholarly journals Article Commentary: The Role of Adjuvant Therapy in Gastrointestinal stromal Tumor after Operative Treatment

2009 ◽  
Vol 2 ◽  
pp. CGast.S3422
Author(s):  
Ka-Ho Lok
Keyword(s):  
High Risk ◽  
Adjuvant Therapy ◽  
Gastrointestinal Stromal Tumor ◽  
Operative Treatment ◽  
Stromal Tumor ◽  
Recurrence Free Survival ◽  
Free Survival

The treatment for localized advance gastrointestinal stromal tumor (GIST) is far from ideal. Up to 50% of patient developed post-operative recurrence and died within 5 years. Recently, imatinib was found to significantly improve recurrence-free survival in post-operative patients. The role of adjuvant therapy in high risk GIST patients is discussed.

The critical role of lymph node dissection in selecting high-risk nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy

2019 ◽  
Vol 37 (4) ◽  
pp. 293.e25-293.e30 ◽  
Author(s):  
Paolo Capogrosso ◽  
Alessandro Larcher ◽  
Alessandro Nini ◽  
Fabio Muttin ◽  
Francesco Cianflone ◽  
...  
Keyword(s):  
Lymph Node ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Lymph Node Dissection ◽  
Renal Cancer ◽  
Critical Role ◽  
Node Dissection

scholarly journals Malignant ossifying fibromyxoid tumor of the brain treated with post-operative fractionated stereotactic radiation therapy: A case report and literature review

2021 ◽  
Vol 12 ◽  
pp. 588
Author(s):  
Sasha Beyer ◽  
Nikhil T. Sebastian ◽  
Rahul Neal Prasad ◽  
Jacqueline Chu ◽  
Kevin Liu ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Stereotactic Radiation Therapy ◽  
Soft Tissue Neoplasm ◽  
Stereotactic Radiation ◽  
Fractionated Stereotactic Radiation Therapy ◽  
The Brain ◽  
Ossifying Fibromyxoid Tumor

Background: Ossifying fibromyxoid tumor (OFMT) is a rare musculoskeletal soft-tissue neoplasm of uncertain histogenesis most frequently occurring in the lower extremities. Conventionally, considered benign, these tumors are often managed by surgical resection followed by surveillance. However, malignant OFMTs with an increased propensity for local recurrence and distant metastasis have been recently identified, and the role of adjuvant therapy in these more aggressive cases is unclear. Case Description: We present, to the best of our knowledge, the first reported case of a primary, malignant, and intracranial OFMT. A 29-year-old female presented with recurrent headaches secondary to a large mass in her right frontal lobe. She underwent gross total resection of the brain mass with final pathology consistent with malignant OFMT demonstrating high-risk features including increased cellularity, grade, and mitotic activity. Due to these high-risk features, she received postoperative fractionated stereotactic radiation therapy (FSRT) to the resection cavity, and to the best of our knowledge, she represents the only known patient with OFMT to be treated with adjuvant FSRT. She tolerated the adjuvant treatment well with no acute or late toxicities and remains disease-free over 5 ½ years after resection. Conclusion: Adjuvant FSRT appears to be a safe and efficacious approach for managing this rare intracranial disease presentation. We review this patient’s clinical course in the context of the literature to demonstrate the difficulties associated with accurate diagnosis of this rare tumor and the controversial role of adjuvant therapy in preventing disease recurrence in this patient population.

The critical role of lymph node dissection in selecting high-risk non-metastatic renal cancer candidates for adjuvant therapy after nephrectomy

2019 ◽  
Vol 18 (1) ◽  
pp. e1175-e1176
Author(s):  
P. Capogrosso ◽  
A. Larcher ◽  
C.A. Bravi ◽  
A. Nini ◽  
P. Dell’Oglio ◽  
...  
Keyword(s):  
Lymph Node ◽  
High Risk ◽  
Adjuvant Therapy ◽  
Lymph Node Dissection ◽  
Renal Cancer ◽  
Critical Role ◽  
Node Dissection ◽  
Metastatic Renal Cancer
Sign in / Sign up

Export Citation Format

Share Document